Can Fite Biopharma Ltd (CANF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.568x

Based on the latest financial reports, Can Fite Biopharma Ltd (CANF) has a cash flow conversion efficiency ratio of -0.568x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-2.38 Million ≈ $-6.37K USD) by net assets (ILA4.18 Million ≈ $11.22K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Can Fite Biopharma Ltd - Cash Flow Conversion Efficiency Trend (2010–2025)

This chart illustrates how Can Fite Biopharma Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Can Fite Biopharma Ltd for a breakdown of total debt and financial obligations.

Can Fite Biopharma Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Can Fite Biopharma Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shiva Mills Limited NSE:SHIVAMILLS	0.044x
Biofil Chemicals & Pharmaceuticals Limited NSE:BIOFILCHEM	-0.167x
CPI Computer Peripherals International AT:CPI	0.042x
Kandal M Venture Limited Class A Ordinary Shares NASDAQ:FMFC	-0.124x
Carlin Gold Corporation V:CGD	-0.003x
Bang Overseas Limited NSE:BANG	-0.049x
ISE Commerce Company Limited KQ:069920	-0.024x
ScandiDos AB ST:SDOS	0.015x

Annual Cash Flow Conversion Efficiency for Can Fite Biopharma Ltd (2010–2025)

The table below shows the annual cash flow conversion efficiency of Can Fite Biopharma Ltd from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Can Fite Biopharma Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	ILA5.59 Million ≈ $15.00K	ILA-9.69 Million ≈ $-25.97K	-1.732x	-23.28%
2024-12-31	ILA5.44 Million ≈ $14.57K	ILA-7.64 Million ≈ $-20.47K	-1.405x	-3.92%
2023-12-31	ILA6.24 Million ≈ $16.74K	ILA-8.44 Million ≈ $-22.63K	-1.352x	+44.03%
2022-12-31	ILA4.47 Million ≈ $11.99K	ILA-10.80 Million ≈ $-28.96K	-2.415x	-252.36%
2021-12-31	ILA14.38 Million ≈ $38.56K	ILA-9.86 Million ≈ $-26.43K	-0.685x	+65.49%
2020-12-31	ILA6.07 Million ≈ $16.28K	ILA-12.06 Million ≈ $-32.34K	-1.986x	+55.24%
2019-12-31	ILA2.44 Million ≈ $6.55K	ILA-10.83 Million ≈ $-29.05K	-4.437x	-221.93%
2018-12-31	ILA3.02 Million ≈ $8.08K	ILA-4.16 Million ≈ $-11.14K	-1.378x	+55.81%
2017-12-31	ILA3.05 Million ≈ $8.19K	ILA-9.52 Million ≈ $-25.53K	-3.118x	-35.33%
2016-12-31	ILA3.87 Million ≈ $10.39K	ILA-8.93 Million ≈ $-23.93K	-2.304x	-417.41%
2015-12-31	ILA10.44 Million ≈ $28.00K	ILA-4.65 Million ≈ $-12.47K	-0.445x	+58.32%
2014-12-31	ILA6.86 Million ≈ $18.38K	ILA-7.33 Million ≈ $-19.64K	-1.069x	+44.80%
2013-12-31	ILA4.46 Million ≈ $11.95K	ILA-8.63 Million ≈ $-23.14K	-1.936x	-131.52%
2012-12-31	ILA-707.99K ≈ $-1.90K	ILA-4.35 Million ≈ $-11.66K	6.141x	+467.80%
2011-12-31	ILA3.29 Million ≈ $8.82K	ILA-5.50 Million ≈ $-14.73K	-1.670x	-497.22%
2010-12-31	ILA13.07 Million ≈ $35.05K	ILA-3.65 Million ≈ $-9.80K	-0.280x	--

About Can Fite Biopharma Ltd

TA:CANF Israel Biotechnology

Market Cap

$6.00 Million

ILA2.24 Billion ILA

Market Cap Rank

#28007 Global

#407 in Israel

Share Price

ILA522.00

Change (1 day)

+10.13%

52-Week Range

ILA1.00 - ILA1500.00

All Time High

ILA1500.00